JP2018509935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509935A5 JP2018509935A5 JP2017567526A JP2017567526A JP2018509935A5 JP 2018509935 A5 JP2018509935 A5 JP 2018509935A5 JP 2017567526 A JP2017567526 A JP 2017567526A JP 2017567526 A JP2017567526 A JP 2017567526A JP 2018509935 A5 JP2018509935 A5 JP 2018509935A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- complex
- peptide
- seq
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 230000000890 antigenic effect Effects 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229940122985 Peptide agonist Drugs 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 4
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 241000283070 Equus zebra Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009813 cataract 31 multiple types Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021059082A JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015000580 | 2015-03-16 | ||
| EPPCT/EP2015/000580 | 2015-03-16 | ||
| EPPCT/EP2015/002244 | 2015-11-09 | ||
| EP2015002244 | 2015-11-09 | ||
| PCT/EP2016/000471 WO2016146260A1 (en) | 2015-03-16 | 2016-03-16 | A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021059082A Division JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509935A JP2018509935A (ja) | 2018-04-12 |
| JP2018509935A5 true JP2018509935A5 (enExample) | 2019-03-22 |
| JP6862369B2 JP6862369B2 (ja) | 2021-04-21 |
Family
ID=55066559
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567525A Active JP6882207B2 (ja) | 2015-03-16 | 2016-03-16 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2017567526A Active JP6862369B2 (ja) | 2015-03-16 | 2016-03-16 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2017567527A Active JP6993240B2 (ja) | 2015-03-16 | 2016-03-16 | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021059082A Active JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021078278A Active JP7190528B2 (ja) | 2015-03-16 | 2021-05-06 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567525A Active JP6882207B2 (ja) | 2015-03-16 | 2016-03-16 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567527A Active JP6993240B2 (ja) | 2015-03-16 | 2016-03-16 | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021059082A Active JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021078278A Active JP7190528B2 (ja) | 2015-03-16 | 2021-05-06 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20180133327A1 (enExample) |
| EP (4) | EP3270954A1 (enExample) |
| JP (5) | JP6882207B2 (enExample) |
| KR (2) | KR102212451B1 (enExample) |
| CN (1) | CN107428845A (enExample) |
| AU (5) | AU2016232659B2 (enExample) |
| CA (3) | CA2973747A1 (enExample) |
| CL (1) | CL2017002345A1 (enExample) |
| CY (1) | CY1122953T1 (enExample) |
| DK (3) | DK3693009T3 (enExample) |
| EA (1) | EA038049B1 (enExample) |
| ES (3) | ES2781455T3 (enExample) |
| HR (1) | HRP20200491T1 (enExample) |
| HU (3) | HUE066851T2 (enExample) |
| IL (2) | IL253416B (enExample) |
| LT (1) | LT3270955T (enExample) |
| MX (1) | MX2017011796A (enExample) |
| NZ (1) | NZ733762A (enExample) |
| PH (1) | PH12017501287A1 (enExample) |
| PL (3) | PL3693009T3 (enExample) |
| PT (2) | PT3270955T (enExample) |
| RS (1) | RS60089B1 (enExample) |
| SI (1) | SI3270955T1 (enExample) |
| WO (5) | WO2016146143A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| US10953003B2 (en) | 2015-12-14 | 2021-03-23 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3389652B1 (en) | 2015-12-14 | 2022-09-28 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
| RU2769314C1 (ru) | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109562106B (zh) | 2016-06-21 | 2023-03-21 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| IL302345B2 (en) | 2016-10-07 | 2024-12-01 | Enterome S A | Immunogenic compounds for cancer therapy |
| EP3522916A2 (en) * | 2016-10-07 | 2019-08-14 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| CN110088136A (zh) * | 2016-10-13 | 2019-08-02 | 达纳-法伯癌症研究所有限公司 | 使用基因表达签名预测黑素瘤中对于ctla4封锁的应答和耐药性的组合物和方法 |
| KR101875055B1 (ko) * | 2016-10-19 | 2018-07-06 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| KR102007203B1 (ko) * | 2016-10-20 | 2019-08-05 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| EP3532505A4 (en) * | 2016-10-25 | 2019-12-25 | Urogen Pharma Ltd. | BODY CAVES IMMUNODULATING TREATMENTS |
| EP3579885A4 (en) * | 2017-02-07 | 2020-12-16 | Nantcell, Inc. | MAXIMIZING T CELL MEMORY, COMPOSITIONS AND RELATED METHODS |
| BR112019020853A2 (pt) | 2017-04-04 | 2020-05-12 | Avidea Technologies, Inc. | Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune |
| US12121573B2 (en) | 2019-07-14 | 2024-10-22 | Tianxin Wang | Methods and agents including STING agonist to treat tumor |
| US11433128B2 (en) * | 2017-04-07 | 2022-09-06 | Tianxin Wang | Cell surface anchoring antigen conjugates to treat cancer |
| WO2018197926A1 (en) * | 2017-04-26 | 2018-11-01 | Robert Penchovsky | Methods for creating novel antibacterial agents using chimeric antisense oligonucleotides |
| CN110996952A (zh) * | 2017-06-21 | 2020-04-10 | X4 制药有限公司 | 用于治疗癌症的方法 |
| WO2019134018A1 (en) * | 2018-01-05 | 2019-07-11 | Telethon Kids Institute | Vaccine conjugates and uses thereof |
| CN111918668A (zh) * | 2018-02-16 | 2020-11-10 | 王天欣 | 治疗肿瘤细胞和癌症的方法和药剂 |
| HRP20230007T1 (hr) * | 2018-04-11 | 2023-03-03 | Enterome S.A. | Antigenski peptidi, namijenjeni sprječavanju i liječenju raka |
| US11447525B2 (en) * | 2018-05-02 | 2022-09-20 | Niigata University | Peptide and use therefor |
| EP3566718A1 (en) | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| EP3820885A4 (en) | 2018-07-11 | 2022-04-20 | The Brigham & Women's Hospital, Inc. | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DRUGS ACROSS THE BLOOD-BRAIN BARRIER |
| US20210290727A1 (en) * | 2018-08-01 | 2021-09-23 | University Of Maryland, Baltimore | MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| US12466892B2 (en) | 2018-11-08 | 2025-11-11 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
| WO2020130548A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 쥐피에이티씨에치4 단백질 유래 세포막 투과 도메인 |
| KR102351041B1 (ko) * | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| WO2020130546A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 씨엘케이2 단백질 유래 세포막 투과 도메인 |
| WO2020130547A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
| JP7659497B2 (ja) * | 2019-01-12 | 2025-04-09 | ザ・メソジスト・ホスピタル | 自己組織化ペプチドナノ粒子およびその使用 |
| CN109859795A (zh) * | 2019-02-20 | 2019-06-07 | 成都分迪科技有限公司 | 泛素化降解目标蛋白质的数据库 |
| US20220184087A1 (en) * | 2019-03-28 | 2022-06-16 | The Penn State Research Foundation | Methods and compositions relating to treatment of cancer |
| US11339190B2 (en) | 2020-04-21 | 2022-05-24 | Rush University Medical Center | Peptides for the treatment of covid-19 |
| US11667678B2 (en) | 2019-04-21 | 2023-06-06 | Rush University Medical Center | Peptides for the treatment of COVID-19 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| SG11202112506SA (en) | 2019-05-10 | 2021-12-30 | Univ California | Modified pluripotent cells |
| EP3827840A1 (en) * | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| AU2021206256A1 (en) * | 2020-01-10 | 2022-07-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| KR102484312B1 (ko) * | 2020-05-14 | 2023-01-02 | 한국화학연구원 | 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| KR102720967B1 (ko) * | 2020-06-04 | 2024-10-23 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물 |
| WO2021263081A2 (en) * | 2020-06-26 | 2021-12-30 | National Breast Cancer Coalition | Breast cancer vaccine |
| MX2023002884A (es) | 2020-09-14 | 2023-03-31 | Boehringer Ingelheim Int | Vacuna heterologa de estimulo primario. |
| KR102556731B1 (ko) * | 2020-09-29 | 2023-07-21 | 주식회사 젠센 | 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물 |
| WO2022079175A1 (en) * | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
| TW202231283A (zh) * | 2020-10-19 | 2022-08-16 | 美商G1治療公司 | 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療 |
| CN113817677B (zh) * | 2021-09-29 | 2023-08-18 | 四川大学 | 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途 |
| WO2023059687A1 (en) * | 2021-10-06 | 2023-04-13 | Whispergenics, Inc. | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of cancers |
| KR102514849B1 (ko) * | 2021-10-28 | 2023-03-28 | 전남대학교산학협력단 | 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물 |
| MX2024011238A (es) | 2022-03-16 | 2024-09-19 | Boehringer Ingelheim Int | Antigenos tumorales, compuestos que comprenden los antigenos tumorales kras, tpx2 o aurka y usos de los mismos. |
| CN119183385A (zh) * | 2022-04-13 | 2024-12-24 | 加利福尼亚大学董事会 | 免疫检查点接合子对免疫细胞的抑制 |
| FR3143031A1 (fr) * | 2022-12-08 | 2024-06-14 | Université Grenoble Alpes | Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles |
| WO2024197792A1 (en) * | 2023-03-31 | 2024-10-03 | Beijing University Of Chinese Medicine | A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof |
| CN119925590A (zh) * | 2025-04-08 | 2025-05-06 | 北京华诺泰生物医药科技有限公司 | 一种mpl复合佐剂及其制备方法和应用 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| PL209127B1 (pl) | 2000-02-23 | 2011-07-29 | Smithkline Beecham Biolog | Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka |
| CA2427858A1 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| GB0218821D0 (en) | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| JP2007519612A (ja) * | 2003-10-15 | 2007-07-19 | イスティチュート スペリオーレ ディ サニータ | 結腸直腸癌抗原 |
| US20080305120A1 (en) | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| AU2006209951B2 (en) * | 2005-02-04 | 2011-04-14 | Survac Aps | Survivin peptide vaccine |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| NZ720288A (en) | 2006-12-27 | 2020-02-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| BRPI0813621A2 (pt) * | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| MX2010001194A (es) | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009130618A2 (en) * | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| EP2303319B1 (en) | 2008-06-20 | 2016-10-05 | Duke University | Compositions, methods and kits for eliciting an immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101040281B1 (ko) | 2008-08-22 | 2011-06-10 | 가톨릭대학교 산학협력단 | Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
| US8074880B2 (en) | 2008-12-01 | 2011-12-13 | Research In Motion Limited | Method, system and mobile device employing enhanced fingerprint authentication |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2755790A1 (en) | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| BRPI1012078A2 (pt) | 2009-05-27 | 2019-09-24 | Glaxosmithkline Biologicals Sa | construto de proteína, composição imunogênica, molécula de ácido nucleico , métodos de induzir uma resposta imune a casb7439 e de tratar um animal humano ou não-humano, e, uso de uma composição imunogênica |
| EP2459594A1 (en) | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| US20120237535A1 (en) * | 2009-09-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Therapeutic Compositions For The Treatment of HPV-Induced Diseases |
| EP2480568B1 (en) | 2009-09-23 | 2016-04-20 | Université Paris Descartes | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011135222A2 (fr) | 2010-04-26 | 2011-11-03 | Universite Joseph Fourier | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| EP4159226A1 (en) | 2010-08-24 | 2023-04-05 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| AU2011303430B2 (en) * | 2010-09-14 | 2014-09-11 | Council Of Scientific And Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
| WO2012048190A1 (en) * | 2010-10-08 | 2012-04-12 | Regents Of The University Of Minnesota | Annexin ii compositions and methods |
| KR101760464B1 (ko) * | 2010-10-13 | 2017-07-24 | 사회복지법인 삼성생명공익재단 | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 |
| SG191830A1 (en) | 2011-01-10 | 2013-08-30 | Cleveland Biolabs Inc | Use of toll-like receptor agonist for treating cancer |
| US9187534B2 (en) | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| US8795678B2 (en) * | 2011-05-13 | 2014-08-05 | Academia Sinica | TLR-2 agonists and methods of use thereof |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| US8819679B2 (en) | 2011-07-28 | 2014-08-26 | International Business Machines Corporation | Methods and systems for on-boarding applications to a cloud |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| PE20141937A1 (es) * | 2011-11-16 | 2014-12-18 | Amgen Inc | Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| US9597393B2 (en) * | 2012-02-09 | 2017-03-21 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (TLR-4) agonist peptides |
| AU2013289372B2 (en) | 2012-07-13 | 2017-11-02 | S-Target Therapeutics Gmbh | Immunoregulatory vaccine |
| JP6306593B2 (ja) * | 2012-09-13 | 2018-04-04 | ユニベルシテ ドゥ ジュネーブ | 細胞透過性ペプチド |
| BR112015006176B1 (pt) | 2012-09-21 | 2023-04-18 | Intensity Therapeutics, Inc | Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular |
| WO2014070663A1 (en) * | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| EP2968407A4 (en) * | 2013-03-13 | 2017-01-04 | Neostem Oncology, LLC | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| CN106061981A (zh) * | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| HUE060293T2 (hu) * | 2013-11-13 | 2023-02-28 | Univ Minnesota | Annexin II variáns készítmények és eljárások |
| KR20160102314A (ko) * | 2014-01-02 | 2016-08-29 | 메모리얼 슬로안-케터링 캔서 센터 | 면역 치료요법에 대한 암 반응의 결정인자 |
| EP3152308A4 (en) * | 2014-06-06 | 2017-12-27 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| JP7523203B2 (ja) | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| CA2966660A1 (en) | 2014-11-13 | 2016-05-19 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| WO2017002345A1 (ja) | 2015-06-29 | 2017-01-05 | パナソニックＩｐマネジメント株式会社 | 冷蔵庫 |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| DK3400290T5 (da) | 2016-01-08 | 2024-09-23 | Replimune Ltd | Onkolytisk virusstamme |
| WO2017120670A1 (en) | 2016-01-11 | 2017-07-20 | Brian Lichty | Oncolytic virus and checkpoint inhibitor combination therapy |
| RU2769314C1 (ru) | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| CN109415705A (zh) | 2016-05-09 | 2019-03-01 | 图恩斯通有限合伙公司 | 组合初免:加强免疫疗法 |
| PL417980A1 (pl) | 2016-07-16 | 2018-01-29 | Univ Warszawski | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| WO2018053508A1 (en) | 2016-09-19 | 2018-03-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| JP7457642B2 (ja) | 2017-04-03 | 2024-03-28 | ビオンテック ユーエス インコーポレイテッド | タンパク質抗原およびその使用 |
| WO2019150310A1 (en) | 2018-02-02 | 2019-08-08 | Novartis Ag | Combination of sting agonist and il-15/il15-ra for the treatment of cancer |
| EP3810151B1 (en) | 2018-06-20 | 2025-08-06 | Yale University | Rig-i agonists and treatments using same |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| MX2023002884A (es) | 2020-09-14 | 2023-03-31 | Boehringer Ingelheim Int | Vacuna heterologa de estimulo primario. |
| WO2022079175A1 (en) | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
-
2015
- 2015-12-22 US US15/557,653 patent/US20180133327A1/en not_active Abandoned
- 2015-12-22 WO PCT/EP2015/002598 patent/WO2016146143A1/en not_active Ceased
-
2016
- 2016-03-16 AU AU2016232659A patent/AU2016232659B2/en active Active
- 2016-03-16 EP EP16711528.6A patent/EP3270954A1/en active Pending
- 2016-03-16 JP JP2017567525A patent/JP6882207B2/ja active Active
- 2016-03-16 ES ES16713731T patent/ES2781455T3/es active Active
- 2016-03-16 CN CN201680015946.2A patent/CN107428845A/zh active Pending
- 2016-03-16 PT PT167115294T patent/PT3270955T/pt unknown
- 2016-03-16 AU AU2016232657A patent/AU2016232657B9/en active Active
- 2016-03-16 LT LTEP16711529.4T patent/LT3270955T/lt unknown
- 2016-03-16 PT PT167137314T patent/PT3270957T/pt unknown
- 2016-03-16 DK DK19219165.8T patent/DK3693009T3/da active
- 2016-03-16 DK DK16713731.4T patent/DK3270957T3/da active
- 2016-03-16 WO PCT/EP2016/000470 patent/WO2016146259A1/en not_active Ceased
- 2016-03-16 ES ES19219165T patent/ES2978792T3/es active Active
- 2016-03-16 PL PL19219165.8T patent/PL3693009T3/pl unknown
- 2016-03-16 HR HRP20200491TT patent/HRP20200491T1/hr unknown
- 2016-03-16 DK DK16711529.4T patent/DK3270955T3/da active
- 2016-03-16 HU HUE19219165A patent/HUE066851T2/hu unknown
- 2016-03-16 EP EP16713731.4A patent/EP3270957B1/en active Active
- 2016-03-16 CA CA2973747A patent/CA2973747A1/en active Pending
- 2016-03-16 CA CA2973757A patent/CA2973757A1/en active Pending
- 2016-03-16 US US15/557,649 patent/US20180133338A1/en not_active Abandoned
- 2016-03-16 AU AU2016232656A patent/AU2016232656A1/en not_active Abandoned
- 2016-03-16 NZ NZ733762A patent/NZ733762A/en unknown
- 2016-03-16 SI SI201630654T patent/SI3270955T1/sl unknown
- 2016-03-16 HU HUE16713731A patent/HUE048808T2/hu unknown
- 2016-03-16 US US15/557,647 patent/US20180133295A1/en not_active Abandoned
- 2016-03-16 WO PCT/EP2016/000472 patent/WO2016146261A1/en not_active Ceased
- 2016-03-16 EP EP16711529.4A patent/EP3270955B1/en active Active
- 2016-03-16 US US15/557,651 patent/US20180133339A1/en not_active Abandoned
- 2016-03-16 PL PL16713731T patent/PL3270957T3/pl unknown
- 2016-03-16 EA EA201792045A patent/EA038049B1/ru unknown
- 2016-03-16 WO PCT/EP2016/000473 patent/WO2016146262A1/en not_active Ceased
- 2016-03-16 CA CA2973770A patent/CA2973770A1/en active Pending
- 2016-03-16 EP EP19219165.8A patent/EP3693009B1/en active Active
- 2016-03-16 ES ES16711529T patent/ES2781454T3/es active Active
- 2016-03-16 HU HUE16711529A patent/HUE048807T2/hu unknown
- 2016-03-16 KR KR1020177029623A patent/KR102212451B1/ko active Active
- 2016-03-16 KR KR1020217003158A patent/KR102386172B1/ko active Active
- 2016-03-16 WO PCT/EP2016/000471 patent/WO2016146260A1/en not_active Ceased
- 2016-03-16 RS RS20200337A patent/RS60089B1/sr unknown
- 2016-03-16 MX MX2017011796A patent/MX2017011796A/es unknown
- 2016-03-16 JP JP2017567526A patent/JP6862369B2/ja active Active
- 2016-03-16 PL PL16711529T patent/PL3270955T3/pl unknown
- 2016-03-16 JP JP2017567527A patent/JP6993240B2/ja active Active
-
2017
- 2017-07-11 IL IL253416A patent/IL253416B/en unknown
- 2017-07-14 PH PH12017501287A patent/PH12017501287A1/en unknown
- 2017-09-15 CL CL2017002345A patent/CL2017002345A1/es unknown
-
2020
- 2020-04-07 CY CY20201100327T patent/CY1122953T1/el unknown
-
2021
- 2021-03-31 JP JP2021059082A patent/JP7179896B2/ja active Active
- 2021-05-06 JP JP2021078278A patent/JP7190528B2/ja active Active
- 2021-08-01 IL IL285273A patent/IL285273B/en unknown
- 2021-08-06 US US17/396,351 patent/US12178788B2/en active Active
- 2021-08-09 US US17/397,447 patent/US12220450B2/en active Active
- 2021-08-18 AU AU2021218097A patent/AU2021218097B2/en active Active
- 2021-12-09 AU AU2021282506A patent/AU2021282506B2/en active Active
- 2021-12-22 US US17/558,906 patent/US12453762B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509935A5 (enExample) | ||
| JP2018510215A5 (enExample) | ||
| JP2018509936A5 (enExample) | ||
| JP2019528693A5 (enExample) | ||
| HRP20200491T1 (hr) | Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma | |
| JP2010516290A5 (enExample) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2012500001A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| JP2014502961A5 (enExample) | ||
| Liu et al. | Treg suppress CTL responses upon immunization with HSP gp96 | |
| JP2019525753A5 (enExample) | ||
| JP2015500827A5 (enExample) | ||
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| RU2015143164A (ru) | Пептиды kntc2 и содержащие их вакцины | |
| JP2009520758A5 (enExample) | ||
| PE20231506A1 (es) | Peptidos y combinaciones de peptidos para su uso en inmunoterapia contra una infeccion por sars-cov-2 (covid-19) | |
| JP2015529677A5 (enExample) | ||
| RU2013158399A (ru) | Пептиды sema5b и содержащие их вакцины | |
| JP2010535504A5 (enExample) | ||
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| JPWO2019197567A5 (enExample) | ||
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины |